ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
Technology Networks

Redefining Early Oncology R&D: What ASCO 2026 Reveals About the Future of Precision-Driven Development

ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
Tech Xplore on MSN

Programmable metasurface generates dozens of holograms at once

Over the past few decades, engineers have developed various devices that can create holograms, three-dimensional (3D) or ...

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
Fierce Pharma

FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

Oryzon Genomics, S.A.: ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPDU.S. patent to expire in March 2043, including 1,095 days of Patent Term AdjustmentNotice of allowance also recei ...

Brain–computer interface detects hidden awareness in unresponsive patients

A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...
Rutland Herald

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily ...

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...